May 4, 2021 07:18 AM EDTUpdated 03:45 PM

Covid-19 roundup: EMA begins rolling review of first Chinese vaccine; After 100% efficacy trial, teenagers could be eligible for Pfizer's vaccine next week

Josh Sullivan

Nicole DeFeudis

Editor

Sinovac’s shot — which was just effective enough to meet regulatory standards — is now the first Chinese Covid-19 vaccine to be considered by the European Medicines …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Covid-19 roundup: EMA begins rolling review of first Chinese vaccine; After 100% efficacy trial, teenagers could be eligible for Pfizer's vaccine next week

Josh Sullivan

Nicole DeFeudis

Editor

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Novartis to cut 139 jobs in NJ as part of commercial refocus

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Covid-19 roundup: EMA be­gins rolling re­view of first Chi­nese vac­cine; Af­ter 100% ef­fi­ca­cy tri­al, teenagers could be el­i­gi­ble for Pfiz­er's vac­cine next week

Editor

Sign up to read this article for free.

more like this

Covid-19 roundup: EMA begins rolling review of first Chinese vaccine; After 100% efficacy trial, teenagers could be eligible for Pfizer's vaccine next week